Overall cancer incidence is decreasing, whereas melanoma cases are increasing. Conditional survival estimates offer a more accurate prognosis for patients the farther they are from time of diagnosis. The effect of age and stage on a melanoma patient's conditional survival estimate is unknown. Surveillance, Epidemiology, and End Results data were utilized to identify newly diagnosed cutaneous melanoma patients (N = 95 041), from 1998 to 2005, with up to 12 years of follow-up. Estimates of disease-specific survival by stage and age were determined by Cox regression analysis and transformed to estimated conditional 5-year survival. Localized melanoma patients have an excellent 5-year survival at diagnosis and over subsequent years. For patients with localized and regional disease, an age effect is present for disease-specific mortality when comparing older patients (70-79 years) with younger patients (< 30 years): hazard ratio (HR) for mortality 3.79 [95% confidence interval (CI) 3.01-4.84] and HR 2.36 (95% CI 1.93-2.91), respectively. No age effect difference is observed in disease-specific survival for advanced disease: HR 1.14 (95% CI 0.87-1.53). Over time, conditional survival estimates improve for older patients with localized and regional disease. This improvement is not seen in distant disease, neither is the age gradient. Diseasespecific mortality and conditional survival for patients with localized and regional melanomas are initially impacted by older age, with effects dissipating over time. Age does not affect survival in patients with advanced disease. Understanding the conditional 5-year disease-specific survival of melanoma based on age and stage can help patients and physicians, informing decision-making about treatment and surveillance. Melanoma Res 26:77-82
Introduction
Although the overall incidence of cancer has been decreasing over the past 35 years, the incidence of melanoma has shown a nearly 200% increase over the same time period [1] [2] [3] [4] . Recent data have demonstrated that the greatest increases in melanoma incidence have occurred in younger women and older men, with a commensurately increasing risk of mortality, especially in older men [2, [4] [5] [6] [7] . Cancer stage is considered the most important prognostic factor for melanoma patients, but there is a fair amount of heterogeneity within stage groupings. As such, the natural history of melanoma is incompletely defined, with some patients having an excellent likelihood of long-term survival and others having an increased risk of death secondary to a tumor with similar clinicopathologic features [1, 5, 6] .
Although the 5-and 10-year survival rates at the time of diagnosis are well described [1] , conditional survival estimates, or the likelihood of survival based on how long a patient has already survived, remain understudied [8] . Conditional survival estimates may be particularly informative for older patients with melanoma, as there appears to be an inverse relationship between increasing age and the incidence of sentinel node positivity [9, 10] , even though older patients have higher overall mortality rates. A better understanding of conditional survival is important for both patients and providers, as it may offer useful information for treatment planning and long-term management strategies.
In this study, we determined conditional 5-year diseasespecific survival for melanoma based on stage and age. The specific effect of age and stage on longer-term melanoma survival is unknown and increasingly important, given the increasing incidence of melanoma in the aging population. We hypothesize that age at diagnosis is an important consideration in conditional survival, and that treatment planning, as well as surveillance strategies for older patients with melanoma, will be better informed by our findings.
Methods

Data source and study population
We used Surveillance, Epidemiology, and End Results (SEER) data to study patients diagnosed with melanoma (N = 95 041) between 1998 and 2005. Only new cases of cutaneous melanoma were included in this analysis; melanoma in situ cases and patients presenting with distant disease from unknown primary sites were excluded. Follow-up data were available for up to 12 years, with a median follow-up time of 6.3 years. Because detailed TNM staging data are not available for this cohort, we used SEER's Collaborative Stage system to define tumor stage as localized, regional, or distant disease. Age was categorized by decades as < 30, 30-39, 40-49, 50-59, 60-69, 70-79, and ≥ 80 years.
As this study uses publically available data that cannot be tracked to human participants, we did not need Institution Review Board approval, on the basis of an exemption from the University of Michigan Institutional Review Board.
Statistical analysis
Using Cox regression, we estimated the disease-specific survival function for each SEER stage. To simplify the presentation of our figures, we initially included age but not sex as a covariate in our models. We later incorporated sex for the purpose of estimating hazard ratios.
The conditional 5-year survival function is defined by the following equation: CS 5 (t) = Pr(T > 5 + t|T > t), where T represents a patient's true survival time in years from diagnosis. That is, given that a patient has survived t years past diagnosis, CS 5 (t) is the probability that he or she will survive an additional 5 years. Applying the definition of conditional probability, we obtain the following equation: CS 5 (t) = Pr(T > 5 + t)/Pr(T > t) = S(5 + t)/ S(t), where S is the survival function. Using this equation, we estimated CS 5 (t) by first estimating S(5 + t) and S(t) through Cox regression.
Results
Clinicopathologic characteristics of the study population are shown in Table 1 . The sex distribution was roughly equal (43.5% female and 56.5% male), but melanoma was more common among white patients, accounting for 95.4% of all melanoma diagnoses. Nearly 30% of all patients were 70 years or older. A large proportion (84.2%) of patients had localized disease. Only 3.8% of all melanoma patients had distant metastases at time of initial diagnosis. Because of this, the overall prognosis for melanoma was generally good and, at time of censoring, only 10% of all melanoma patients had died from their cancer.
Disease-specific mortality is influenced by age and sex. Increasing age is associated with a worse prognosis. There is a linear relationship between age and diseasespecific mortality. The effect of age (grouped by decade of age) is seen in every stage, although the strongest association with mortality is seen in the oldest patients with localized disease. For example, the hazard ratio Table 2 ]. Figure 1 illustrates the conditional 5-year disease-specific survival of patients with localized melanoma by age group. At the time of diagnosis there is a small age gradient observed between the groups, with better overall survival for younger patients. Over time, younger patients maintain excellent conditional 5-year survival. Initially, older patients have a worse prognosis, but after the first year of diagnosis, their likelihood of surviving the next 5 years improves. Further, the longer an older patient survives, the greater the gains in his/her 5-year conditional survival. With the passage of time, the survival difference based on age decreases, with a narrowing of the age gradient, and age becomes less of an influence on survival. Figure 2 shows the conditional 5-year disease-specific survival of patients with regional melanoma, noting a clear age gradient. Here, younger patients clearly have better survival rates than older patients at the time of diagnosis. However, as time goes on (years past the time of initial diagnosis), there is a decrease in the survival gradient between the age groups. Interestingly, survival for older patients approaches that for the younger patients, with age becoming less of a survival factor over time. The findings demonstrate that the longer an older patient survives, the higher the likelihood that he/she will survive for another 5 years, even when compared with younger patients with a similar stage of disease.
The conditional 5-year disease-specific survival of patients with distant disease shows that the longer melanoma patients survive, the better the likelihood that they will survive for another 5 years (Fig. 3) . Despite an initially poor prognosis in patients with distant disease, conditional 5-year survival improves more rapidly with time in these patients than in patients with regional disease. Interestingly, age does not differentially impact survival in melanoma patients with distant metastases over time, and no age gradient is seen between older and younger patients. Similar to the findings with traditional estimates of disease-specific mortality (Table 2) , there is no significant association between age and conditional survival for patients with distant metastases.
Discussion
The results of this study provide information to patients and providers on the conditional 5-year disease-specific survival of patients with melanoma. We found that increasing age at the time of diagnosis was associated with worse disease-specific mortality in localized and regional melanomas. The conditional 5-year diseasespecific survival of localized melanoma was generally excellent, but importantly, patients with regional and distant melanomas demonstrated improvements in conditional survival with time. In regional disease, older patients appeared to have greater gains in conditional survival compared with younger patients. Interestingly, patients with distant disease gained the most survival benefit with time, and there did not appear to be survival differences on the basis of age.
Although conditional survival has been studied in melanoma, to date, studies have not focused on the specific implications of age and stage [8, [11] [12] [13] . The incidence of melanoma is rising [1,2,4], and it is now the fifth most common cancer in the USA, mostly attributed to an increase in diagnosis among younger women and older men [2, 6] . Treatment decisions for older patients are somewhat controversial, and there appears to be an underutilization of sentinel node biopsy and complete lymph node dissection and use of systemic agents (as adjuvant treatment in regional disease or as directed treatment in advanced disease) in the elderly population [7, [14] [15] [16] [17] . Although a melanoma diagnosis is generally associated with excellent outcomes, more advanced stages of the disease carry a far worse prognosis [6] . With advances in multimodal treatment options for advanced melanoma, it is becoming increasingly important to understand the implications of advancing age on longerterm survival, as estimated by conditional survival probabilities.
Recent work has demonstrated an important role for age as a prognostic variable, with investigators citing much poorer outcomes for elderly patients [4, 5] . Indeed, age is an important factor in conditional 5-year survival in localized and regional melanomas. Here, we show similar trends, with worse initial estimates of survival with advancing age. However, the conditional survival estimates demonstrate that the age gradient, or negative impact of age, narrows with time in patients with localized and regional disease. Prior studies have used an age of 50 years as the binomial cutoff point, obscuring the effects of more advanced age at diagnosis [18, 19] . One European study demonstrated an improvement in conditional survival estimates by age, with a narrowing of the age gradient for melanoma patients; however, this was not further analyzed by stage [12] .
By evaluating increasing age by decade, our results demonstrate the importance of considering conditional survival rates in elderly patients, as those who continue to survive after their initial diagnosis actually do very well. In fact, elderly patients with regional disease seem to have the most to gain over time, as their conditional survival rates actually improve more than that in younger patients. This has important implications for decisionmaking on treatment options for older patients, supporting a role for appropriate use of wide excision and sentinel node biopsy when clinically indicated [17] . Going forward, these findings may inform the use of adjuvant therapies, even in older populations.
Interestingly, there is no noted age gradient in survival rates for patients with distant melanoma. Here, elderly patients who survive after their initial diagnosis actually do just as well as their younger counterparts. Because of the increasing incidence of high-risk melanoma in older men, our findings have important implications for decision-making with regard to patient selection for potentially effective systemic treatments. Many studies have restricted the use of immunotherapy in older patients because of toxicity concerns, but the current data suggest that older patients may in fact have as much to gain (if not more to gain) from treatment as younger patients. Strong consideration should be given to use of Conditional 5-year disease-specific survival for localized melanoma patients by age group. Conditional 5-year disease-specific survival for regional melanoma patients by age group.
systemic treatment on the basis performance status and comorbidities rather than age alone. Further, our results support the need for continued studies on tumor biology and host response in elderly patients with melanoma.
The findings of this study are relevant to both physicians and patients. Understanding the conditional 5-year disease-specific survival allows physicians to create appropriate management plans and allows patients to have a more accurate assessment of their life expectancy. A melanoma patient with regional or distant disease who has survived 3 years after diagnosis has a very different 5-year life expectancy than what he/she had at time of diagnosis, representing 'credit for time served'. Our results also highlight the importance of appropriate treatment (surgical treatment for localized/regional disease and systemic treatment for distant disease), even in more elderly age groups.
There are limitations to this study. SEER data are limited in their reporting of comorbid conditions and receipt of systemic treatment. However, SEER is a populationbased dataset and likely very reflective of generalizable national outcomes. Another limitation is that SEER does not include information about systemic treatments.
Although newer therapeutics (e.g. vemurafenib, dabrafenib, trametinib, ipilimumab, pembrolizumab, and nivolumab) must be considered in contemporary discussions about survival with advanced melanoma, there were no meaningful treatments during the time span of this study cohort (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) . The increasing use of effective systemic treatments will likely change point estimates of disease-specific survival, but their impact on future estimates of conditional survival are currently unknown. Another potential limitation is that, although diseasespecific survival rates are standard outcome measures, they can underestimate actual cancer-related deaths [20] . This would have the possible effect of slightly overestimating our results in the context of how conditional survival influences long-term outcomes.
The results of this study provide information on the conditional 5-year disease-specific survival for melanoma on the basis age and stage, which gives a more pertinent survival estimation the further a patient is from the time of diagnosis. Initially, older age is associated with a poorer prognosis. However, in localized and regional disease, age becomes less of a detrimental factor in conditional survival estimates as time goes on. Interestingly, patients with distant disease gained the most survival benefit with time, and there did not appear to be conditional survival differences based on age at all. As the number of older patients diagnosed with advanced stage melanoma continues to increase, management of these patients will continue to be a challenge. Our findings help inform clinical decision-making, suggesting that we should be more cognizant of age bias in treatment decisions. Conditional 5-year disease-specific survival for distant melanoma patients by age group.
